Advertisement
Canada markets close in 55 minutes
  • S&P/TSX

    22,198.96
    +91.88 (+0.42%)
     
  • S&P 500

    5,257.51
    +9.02 (+0.17%)
     
  • DOW

    39,807.04
    +46.96 (+0.12%)
     
  • CAD/USD

    0.7387
    +0.0014 (+0.19%)
     
  • CRUDE OIL

    83.03
    +1.68 (+2.07%)
     
  • Bitcoin CAD

    95,640.28
    +2,620.50 (+2.82%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,240.80
    +28.10 (+1.27%)
     
  • RUSSELL 2000

    2,122.50
    +8.15 (+0.39%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,395.24
    -4.28 (-0.03%)
     
  • VOLATILITY

    12.96
    +0.18 (+1.41%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6843
    +0.0038 (+0.56%)
     

Toronto Exchanges Stock Review BELLUS Health Helius Medical Technologies Resverlogix and Crescita Therapeutics

LONDON, UK / ACCESSWIRE / March 5, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. Access our complimentary up-to-the-minute research reports by becoming an online member now:

www.active-investors.com/registration-sg

The S&P/TSX Composite Index lost 9.36 points, or 0.06%, to close Friday's trading session at 15,384.59. The TSX Venture Exchange shaved off 3.30 points, or 0.40%, to finish at 826.02.

Moreover, the Healthcare index was down by 1.30%, closing at 85.57.

ADVERTISEMENT

Today's stocks of interest consist of BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX). Click the link below to view a sample of the free research report that will be available to you as a member of Active-Investors:

www.active-investors.com/registration-sg

BELLUS Health Inc.

Laval, Canada-based BELLUS Health Inc.'s stock finished Friday's session 4.88% higher at $0.43 with a total volume of 160,477 shares traded. Over the last month and the previous year, BELLUS Health's shares have surged 16.22% and 34.38%, respectively. Shares of the Company, which engages in developing novel therapeutics for conditions with high unmet medical need, are trading above its 50-day and 200-day moving averages. BELLUS Health's 200-day moving average of $0.40 is above its 50-day moving average of $0.39. View the research report on BLU.TO at:

www.active-investors.com/registration-sg/?symbol=BLU

Helius Medical Technologies Inc.

On Friday, shares in Newtown, Pennsylvania headquartered Helius Medical Technologies Inc. recorded a trading volume of 3,000 shares. The stock ended the day 3.38% higher at $15.60. Helius Medical Technologies' stock has gained 26.01% in the last month, 9.09% in the previous three months, and 32.77% in the past year. Shares of the Company, which focuses on the development of products for the treatment of neurological symptoms caused by disease or trauma in the US, are trading above its 50-day moving average. The stock's 200-day moving average of $15.71 is above its 50-day moving average of $13.75. Get the free report on HSM.TO at:

www.active-investors.com/registration-sg/?symbol=HSM

Resverlogix Corp.

On Friday, shares in Calgary, Canada headquartered Resverlogix Corp. ended the session 1.70% higher at $1.79 with a total volume of 6,920 shares traded. Resverlogix's shares have gained 20.95% in the last three months. Shares of the Company, which develops small molecule therapeutics for bromodomain and extra-terminal inhibition in the US and Canada, are trading above 200-day moving average. Furthermore, the stock's 50-day moving average of $1.81 is greater than its 200-day moving average of $1.62. Access the most recent report coverage on RVX.TO at:

www.active-investors.com/registration-sg/?symbol=RVX

Crescita Therapeutics Inc.

Mississauga, Canada headquartered Crescita Therapeutics Inc.'s stock closed the day 3.33% lower at $0.58. The stock recorded a trading volume of 12,046 shares during Friday's session. Crescita Therapeutics' shares have gained 8.31% in the previous three months. Shares of the Company, which provides over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $0.65 is greater than its 200-day moving average of $0.63. Today's complimentary report on CTX.TO can be accessed at:

www.active-investors.com/registration-sg/?symbol=CTX

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors